메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Dimora Medical Recognized as Key Driver in Winner Medical'…

NEW YORK, Dec. 9, 2025 -- Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical's most influential international sub-brands, Dimora Medical played a pivotal role in this achievement, driven by its industry-leading performance in Amazon's wound-care category. "Several years ago, as we watched the advanced wound care market surge in Europe and North America, it became clear t
- 김갑성 기자
- 2025-12-09 18:35
ISLAND HOSPITAL NAMED MALAYSIA'S FIRST FLAGSHIP MEDICAL TOURISM…

GEORGETOWN, Malaysia, Dec. 9, 2025 -- Island Hospital is the winner of Malaysia's first Flagship Medical Tourism Hospital (FMTH) programme, a recognition of its consistent standards in care, safety and patient experience for international patients. Launched in 2022, the three-year programme aimed to identify hospitals that can anchor Malaysia's medical tourism growth globally. Island Hospital, selected as the top performer among four finalists, was the only hospital from Penang. The announcement was made today by Malaysia's Minister of Health, Yang Berhormat Datuk Seri Dr Dzulk
- 김갑성 기자
- 2025-12-09 18:18
Seven Zonta Clubs in Hong Kong unite to promote "Zonta Sa…

HONG KONG, Dec. 9, 2025 -- The recent tragic fire at Tai Po has brought sadness and loss to our community. The seven Zonta Clubs in Hong Kong would like to express our deepest condolences to the victims and to extend our sympathy to all those affected. The swift response from all sectors of society reflects Hong Kong's spirit of helping each other during tough times, while also reminding us of the needs of vulnerable groups. According to the World Health Organization (WHO), violence against women and girls remains the most widespread and pervasive human rights violation globally, affec
- 김갑성 기자
- 2025-12-09 18:05
Dizal Showcases its Strong Hematology Pipeline with New Data…

SHANGHAI, Dec. 9, 2025 -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma. Golidocitinib Newly diagnosed PTCL Two dose regimes of golidocitinib combined with CHOP have been explored for th
- 김갑성 기자
- 2025-12-09 18:00
VSure and HEYDOC Health Introduce CareConnect Suite, Trans…

KUALA LUMPUR, Malaysia, Dec. 9, 2025 -- In a move that reflects the shifting expectations of Malaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launched CareConnect Suite, a new digital ecosystem aimed at closing long-standing gaps in employee benefits for small and medium enterprises (SMEs). The foundation of CareConnect Suite is the combination of EzPA — VSure's uniquely curated, affordable and accessible PA protection with hospital income benefit — and FutureK, HEYDOC Health's digitally integrated outpatient care model.
- 김갑성 기자
- 2025-12-09 15:58
Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 -- As the world's first country to be prescribed for its health benefits, Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy. The Swedish Prescription video shows how it works. With interest in "northern lights travel" on the rise and 61% of travelers naming the aurora borealis as the top natural phenomenon they want to experience, the timing couldn't be better. A rare solar maximum is underway, making aurora displays brighter, more frequent and
- 김갑성 기자
- 2025-12-09 15:53
Phase II Data of Cadonilimab Regimen as Neoadjuvant Ther…

HONG KONG, Dec. 9, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as neoadjuvant therapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was presented at the 2025 ESMO Asia Congress. Currently, Akeso is running the pivotal Phase III study (AK104-310/COMPASSION-33) investigating cadonilimab combined with the SOX regimen for perio
- 김갑성 기자
- 2025-12-09 15:50
GC Genome Study Identifies 'Confounders' Interfering with Can…

YONGIN, South Korea, Dec. 9, 2025 -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in Clinical Chemistry (Impact Factor 6.3, 2025). The findings reveal key physiological factors that can interfere with cancer-associated cfDNA signals, offering a foundation for improving the accuracy of liquid biopsy tests. The study, conducted in collaboration with Professor Min-Jung Kwon and her team at Kangbuk Samsung Medical Center,
- 김갑성 기자
- 2025-12-09 14:54
CGTN: 비극을 딛고 재건을 위해 하나로 뭉친 홍콩

[ 메디채널 김갑성 기자 ] 베이징 2025년 12월 9일 -- CGTN이 홍콩 특별행정구(HKSAR) 타이포에서 발생한 참사 이후의 구호 활동과 재건 노력을 다룬 기사를 보도했다. 이 기사는 중앙 정부, 홍콩 특별행정구 정부, 홍콩 주민, 중국 본토 자원봉사자, 그리고 사회 각계각층의 일치단결한 대응을 조명하고 있다. 타이포의 왕푹 코트(Wang Fuk Court) 아파트 단지 주민들은 11월 26일의 참담한 화재 이후 처음으로 잿더미가 된 집을 조용히 찾아와 상태를 살폈다. 대다수 주민은 가져갈 수 있는 얼마 안 되는 물건을 챙기고자 그곳을 찾았다. 하지만 그들은 혼자가 아니었다. 수많은 자원봉사자가 피해 주민의 짐 정리를 돕고 대기 중이던 승합차로 주민들을 안내했다. 근처에는 생수와 포장 물품이 가득 실린 트럭이 뒷문을 연 채로 주차되어 있었다. 운전석은 비어 있었지만, 필요한 사람은 누구나 무료로 구호 물품을 가져갈 수 있었다. 도움의 손길을 내민 이들 중에는 58세의 택시 운전사인 웡 치추엔(Wong Chi-chuen) 씨도 있었다. 웡 씨는 동료 기사들과 함께 5일 내내 주민들을 무료로 태워다
- 김갑성 기자
- 2025-12-09 14:41
Greenyn Biotechnology Launches Insumate® mcIRBP-19 Bitt…

TAICHUNG, Dec. 9, 2025 -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingredients continues to rise, Greenyn Biotechnology Co., Ltd., a publicly listed biotechnology company in Taiwan, announced today that its flagship ingredient Insumate® mcIRBP-19 Bitter Melon Peptide has been awarded the "Excellent Product Quality Certification" by the Taiwan Complementary Medic
- 김갑성 기자
- 2025-12-09 10:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분